UnitedHealth Group Incorporated (UNH) Receives Consensus Rating of “Buy” from Brokerages
Shares of UnitedHealth Group Incorporated (NYSE:UNH) have been assigned an average recommendation of “Buy” from the twenty-five ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and twenty-four have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $200.98.
A number of equities analysts recently commented on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $192.00 price objective on shares of UnitedHealth Group in a research note on Friday, May 19th. Vetr downgraded shares of UnitedHealth Group from a “buy” rating to a “hold” rating and set a $179.00 target price for the company. in a research report on Monday, April 24th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $205.00 target price (up previously from $200.00) on shares of UnitedHealth Group in a research report on Saturday, April 22nd. Zacks Investment Research upgraded shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $201.00 target price for the company in a research report on Wednesday, June 7th. Finally, Barclays PLC increased their target price on shares of UnitedHealth Group from $200.00 to $217.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 19th.
WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/unitedhealth-group-incorporated-unh-receives-consensus-rating-of-buy-from-brokerages/1473364.html.
In other news, Director William C. Ballard, Jr. sold 5,000 shares of the firm’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $193.98, for a total transaction of $969,900.00. Following the transaction, the director now owns 76,058 shares in the company, valued at approximately $14,753,730.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gail R. Wilensky sold 5,540 shares of the firm’s stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $178.74, for a total transaction of $990,219.60. Following the transaction, the director now owns 60,516 shares in the company, valued at approximately $10,816,629.84. The disclosure for this sale can be found here. Insiders have sold a total of 15,540 shares of company stock worth $2,873,320 in the last 90 days. 0.89% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Harbour Capital Advisors LLC increased its position in UnitedHealth Group by 18,383.4% in the second quarter. Harbour Capital Advisors LLC now owns 2,516,706 shares of the healthcare conglomerate’s stock worth $13,573,000 after buying an additional 2,503,090 shares in the last quarter. Jennison Associates LLC increased its position in UnitedHealth Group by 180.4% in the second quarter. Jennison Associates LLC now owns 2,252,507 shares of the healthcare conglomerate’s stock worth $417,660,000 after buying an additional 1,449,130 shares in the last quarter. Thrivent Financial For Lutherans increased its position in UnitedHealth Group by 346.7% in the second quarter. Thrivent Financial For Lutherans now owns 1,690,187 shares of the healthcare conglomerate’s stock worth $313,394,000 after buying an additional 1,311,773 shares in the last quarter. State Street Corp increased its position in UnitedHealth Group by 2.5% in the first quarter. State Street Corp now owns 45,724,509 shares of the healthcare conglomerate’s stock worth $7,499,276,000 after buying an additional 1,122,534 shares in the last quarter. Finally, BlackRock Inc. increased its position in UnitedHealth Group by 1.2% in the second quarter. BlackRock Inc. now owns 69,430,416 shares of the healthcare conglomerate’s stock worth $12,873,786,000 after buying an additional 796,654 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.
Shares of UnitedHealth Group (NYSE UNH) traded up 0.325% during midday trading on Friday, hitting $193.195. The stock had a trading volume of 1,503,292 shares. The firm has a 50 day moving average of $189.18 and a 200-day moving average of $174.51. The company has a market cap of $186.79 billion, a P/E ratio of 23.209 and a beta of 0.64. UnitedHealth Group has a one year low of $132.39 and a one year high of $196.04.
UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings data on Tuesday, July 18th. The healthcare conglomerate reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.08. UnitedHealth Group had a net margin of 4.32% and a return on equity of 21.52%. The firm had revenue of $50.05 billion during the quarter, compared to analyst estimates of $49.97 billion. During the same quarter last year, the business posted $1.96 EPS. The company’s revenue was up 7.7% on a year-over-year basis. On average, analysts forecast that UnitedHealth Group will post $9.87 earnings per share for the current fiscal year.
About UnitedHealth Group
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.